166 related articles for article (PubMed ID: 22791222)
21. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis.
Rolle AS; Zimmermann B; Poon SH
J Clin Rheumatol; 2013 Mar; 19(2):90-3. PubMed ID: 23364662
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
23. Effect of etanercept on iritis in patients with ankylosing spondylitis.
Rosenbaum JT
Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
[No Abstract] [Full Text] [Related]
24. The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: results of 2-year follow-up.
Yilmaz H; Kocabas H; Erkin G
Acta Reumatol Port; 2013; 38(4):299-301. PubMed ID: 24435036
[TBL] [Abstract][Full Text] [Related]
25. Demyelination during anti-TNFα therapy for ankylosing spondylitis.
Mercieca C; Vella N; Borg AA
Mod Rheumatol; 2012 Apr; 22(2):303-7. PubMed ID: 21748364
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
27. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.
Kobak S; Oksel F; Kabasakal Y; Doganavsargil E
Clin Rheumatol; 2007 Dec; 26(12):2191-2194. PubMed ID: 17611708
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
[TBL] [Abstract][Full Text] [Related]
29. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
30. Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.
Kaffenberger B; Haverkos B; Tyler K; Wong HK; Porcu P; Gru AA
Am J Dermatopathol; 2015 Aug; 37(8):604-13. PubMed ID: 25839892
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
33. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
34. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
36. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.
Hammoudeh M; Zack DJ; Li W; Stewart VM; Koenig AS
J Int Med Res; 2013 Aug; 41(4):1150-9. PubMed ID: 23803306
[TBL] [Abstract][Full Text] [Related]
37. Development of angioimmunoblastic T-cell lymphoma after treatment of diffuse large B-cell lymphoma: a case report and review of literature.
Wang Y; Xie B; Chen Y; Huang Z; Tan H
Int J Clin Exp Pathol; 2014; 7(6):3432-8. PubMed ID: 25031772
[TBL] [Abstract][Full Text] [Related]
38. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
39. [RS3PE syndrome with angioimmunoblastic T-cell lymphoma early after the start of immunosuppressive therapy].
Ishihara N; Aota Y; Nagata D; Saihara M; Sutoh A; Okabe M; Wakabayasi K; Yokoyama T; Gotoh A
Nihon Ronen Igakkai Zasshi; 2023; 60(1):60-66. PubMed ID: 36889724
[TBL] [Abstract][Full Text] [Related]
40. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.
Taban M; Dupps WJ; Mandell B; Perez VL
Ocul Immunol Inflamm; 2006 Jun; 14(3):145-50. PubMed ID: 16766397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
